Relacorilant + Nab-Paclitaxel in Patients With Recurrent, Platinum-Resistant Ovarian Cancer: A Three-Arm, Randomized, Controlled, Open-Label Phase II Study.
Nicoletta ColomboToon Van GorpUrsula A MatulonisAna OakninRachel N GrishamGini F FlemingAlexander B OlawaiyeDorothy D NguyenAndrew E GreensteinJoseph M CustodioHristina I PashovaIulia C TudorDomenica LorussoPublished in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2023)
< .025). A phase III evaluation of this regimen is underway (ClinicalTrials.gov identifier: NCT05257408).